LivaNova (LIVN) Expected to Post Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect LivaNova to announce earnings of $1.06 per share and revenue of $381.13 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. The company had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. LivaNova’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.05 EPS. On average, analysts expect LivaNova to post $3.78 EPS for the current fiscal year and $4.16 EPS for the next fiscal year.

LivaNova Stock Up 1.6%

Shares of LIVN stock opened at $80.21 on Tuesday. The company’s fifty day simple moving average is $78.52 and its two-hundred day simple moving average is $73.00. LivaNova has a 52 week low of $48.82 and a 52 week high of $85.76. The stock has a market cap of $4.42 billion, a P/E ratio of 23.73 and a beta of 0.87. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on LIVN shares. Mizuho lifted their target price on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Stifel Nicolaus set a $85.00 price target on LivaNova in a research note on Wednesday, August 5th. Needham & Company LLC increased their price target on LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Zacks Research cut LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 price objective (up from $87.00) on shares of LivaNova in a research note on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.75.

Insider Activity at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 3,500 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the sale, the director directly owned 4,434 shares in the company, valued at $345,896.34. This represents a 44.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Brooke Story sold 2,300 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the sale, the director directly owned 7,488 shares of the company’s stock, valued at $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,450 shares of company stock worth $591,839 over the last three months. 0.35% of the stock is currently owned by insiders.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.